Variables
18-64 years n=54 (31.8%) ≥ 65 years n=116 (68.2%)
p value
Sex, n (%) Female Male 14 (25.9) 40 (74.1) 58 (50) 58 (50)
0.003
APACHE II (mean±SD) 20.9±7.6 25.74±6.6 < 0.001
Underlying diseases, n (%) Chronic obstructive pulmonary disease Diabetes mellitus Cardiac failure Coronary artery disease Immunosuppression Solid organ malignancy 17 (31.5) 12 (22.2) 3 (5.6) 5 (9.3) 8 (14.8) 1 (1.9) 69 (59.5) 32 (27.6) 30 (25.9) 35 (30.2) 6 (5.2) 3 (2.6) 0.001 0.457 0.002 0.003 0.067 1.0
Initial serum urea (mg/dL) median (min-max) 39 (11-99) 48 (9-125) 0.041
Initial serum creatinine (mg/dL) median (min-max) 0.65 (0.3-1.2) 0.77 (0.3-1.2) 0.018
COL nephrotoxicity, n (%) 18 (33.3) 88 (75.9) < 0.001
Concomitant nephrotoxic agent use, n (%) 28 (50.3) 83 (65.9) 0.07
Vasopressor agent use, n (%) 13 (24.1) 73 (62.9) < 0.001
End-treatment serum urea (mg/dL) median (min-max) 49 (8-266) 93.5 (10-295) < 0.001
End-treatment serum creatinine (mg/dL) median (min-max) 0.83 (0.21-5.68) 1.96 (0.3-8) < 0.001
14-day mortality, n (%) 12 (22.2) 60 (51.7) < 0.001
28-day mortality, n (%) 15 (34.9) 40 (71.4) < 0.001
Overall mortality, n (%) 35 (64.8) 107 (92.2) < 0.001